CSF3 and acute myeloid leukemia: In our study, these patients showed poor response to initial AML or ALL‐like chemotherapy, but especially sensitive to venetoclax as well as LDAC, G‐CSF, and anthracyclines combination chemotherapy despite the complexity of immunophenotyping and cytogenetics at the first diagnosis.